texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Trastuzumab Deruxtecan Wins Rapid Approval for HER2-Low Breast Cancer

Publication: American Journal of Managed Care
Debra Patt, M.D., Ph.D., MBA, Executive Vice President, Public Policy, Payer Relations, and Strategic Initiatives at Texas Oncology, discussed the rapid approval of Enhertu in HER2-low metastatic breast cancer by the FDA – underscoring the urgency to bring the transformational medicine to patients as quickly as possible.

Click here to read the full article.

Related Physicians